Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c01414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Junli Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences, Nanning, Guangxi 530021, Chi…. Hauptthemen laut MEDLINE: Osteoclasts, Proteolysis Targeting Chimera. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province, Science and Technology Projects of Ganzhou.
Abstract (Originalsprache)
Bruton's tyrosine kinase (BTK) is an attractive target in inflammatory and autoimmune diseases. However, the effectiveness of BTK inhibitors is limited by side effects and drug resistance. In this study, we report the development of novel BTK proteolysis targeting chimeras (PROTACs) with different classes of BTK-targeting ligands (e.g., spebrutinib) other than ibrutinib. Compound 23 was identified as a potent and fast BTK PROTAC degrader, exhibiting outstanding degradation potency and efficiency in Mino cells (DC50, 4 h = 1.29 ± 0.3 nM, t1/2, 20 nM = 0.59 ± 0.20 h). Furthermore, compound 23 forms a stable ternary complex, as confirmed by the HTRF assay. Notably, 23 down-regulated the BTK-PLCγ2-Ca2+-NFATc1 signaling pathway activated by RANKL, thus inhibiting osteoclastogenesis and attenuating alveolar bone resorption in a mouse periodontitis model. These findings suggest that compound 23 is a potent and promising candidate for osteoclast-related inflammatory diseases, expanding the potential of BTK PROTACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences, Nanning, Guangxi 530021, China.
- Department of Stomatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Jiangxi Province Key Laboratory of Biomaterials and Biofabrication for Tissue Engineering, School of Phar…
- Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- Department of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
- Instrumental Analysis Center, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China.
ORCID-Profile: Jianjun Chen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
- Science and Technology Projects of Ganzhou
Zitieren
APA
Huang, J., Ma, Z., Peng, X., Yang, Z., Wu, Y., Zhong, G., Ouyang, T., Chen, Z., Liu, Y., Wang, Q., Chen, J., Chen, T., & Zeng, Z. (2024). Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01414
Vancouver
Huang J, Ma Z, Peng X, Yang Z, Wu Y, Zhong G, et al. Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01414
BibTeX
@article{Huang2024,
author = {Huang, Junli and Ma, Zeli and Peng, Xiaopeng and Yang, Zichao and Wu, Yuhao and Zhong, Guanghong and Ouyang, Tianfeng and Chen, Zhen and Liu, Yao and Wang, Qirui and Chen, Jianjun and Chen, Ting and Zeng, Zhenhua},
title = {Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c01414}
}
EUVIMED